These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

193 related items for PubMed ID: 20816118

  • 21. Targeting cardiovascular risk associated with both low density and high density lipoproteins using statin-niacin combination therapy.
    Duvall WL, Blazing MA, Saxena S, Guyton JR.
    J Cardiovasc Risk; 2002 Dec; 9(6):339-47. PubMed ID: 12478203
    [Abstract] [Full Text] [Related]

  • 22. Effectiveness of the addition of ezetimibe to ongoing statin therapy in modifying lipid profiles and attaining low-density lipoprotein cholesterol goals in older and elderly patients: subanalyses of data from a randomized, double-blind, placebo-controlled trial.
    Pearson T, Denke M, McBride P, Battisti WP, Brady WE, Palmisano J.
    Am J Geriatr Pharmacother; 2005 Dec; 3(4):218-28. PubMed ID: 16503317
    [Abstract] [Full Text] [Related]

  • 23. Comparison of the safety and efficacy of a combination tablet of niacin extended release and simvastatin vs simvastatin monotherapy in patients with increased non-HDL cholesterol (from the SEACOAST I study).
    Ballantyne CM, Davidson MH, McKenney J, Keller LH, Bajorunas DR, Karas RH.
    Am J Cardiol; 2008 May 15; 101(10):1428-36. PubMed ID: 18471454
    [Abstract] [Full Text] [Related]

  • 24. Efficacy and safety of rosuvastatin and fenofibric acid combination therapy versus simvastatin monotherapy in patients with hypercholesterolemia and hypertriglyceridemia: a randomized, double-blind study.
    Roth EM, McKenney JM, Kelly MT, Setze CM, Carlson DM, Gold A, Stolzenbach JC, Williams LA, Jones PH.
    Am J Cardiovasc Drugs; 2010 May 15; 10(3):175-86. PubMed ID: 20524719
    [Abstract] [Full Text] [Related]

  • 25. Pravastatin and fenofibrate in combination (Pravafenix(®)) for the treatment of high-risk patients with mixed hyperlipidemia.
    Farnier M.
    Expert Rev Cardiovasc Ther; 2012 May 15; 10(5):565-75. PubMed ID: 22651832
    [Abstract] [Full Text] [Related]

  • 26. Comparison of effects of simvastatin alone versus fenofibrate alone versus simvastatin plus fenofibrate on lipoprotein subparticle profiles in diabetic patients with mixed dyslipidemia (from the Diabetes and Combined Lipid Therapy Regimen study).
    May HT, Anderson JL, Pearson RR, Jensen JR, Horne BD, Lavasani F, Yannicelli HD, Muhlestein JB.
    Am J Cardiol; 2008 Feb 15; 101(4):486-9. PubMed ID: 18312763
    [Abstract] [Full Text] [Related]

  • 27. Baseline lipoprotein lipids and low-density lipoprotein cholesterol response to prescription omega-3 acid ethyl ester added to Simvastatin therapy.
    Maki KC, Dicklin MR, Davidson MH, Doyle RT, Ballantyne CM, COMBination of prescription Omega-3 with Simvastatin (COMBOS) Investigators.
    Am J Cardiol; 2010 May 15; 105(10):1409-12. PubMed ID: 20451686
    [Abstract] [Full Text] [Related]

  • 28. [Long-term hypolipidemic treatment of mixed hyperlipidemia with a combination of statins and fibrates].
    Zeman M, Zák A, Vecka M, Romaniv S.
    Cas Lek Cesk; 2003 Aug 15; 142(8):500-4. PubMed ID: 14626567
    [Abstract] [Full Text] [Related]

  • 29. Comparative efficacy and safety of fenofibrate/pravastatin plus ezetimibe triple therapy and simvastatin/ezetimibe dual therapy in type 2 diabetic patients with mixed hyperlipidaemia and cardiovascular disease.
    Farnier M, Retterstøl K, Steinmetz A, Császár A.
    Diab Vasc Dis Res; 2012 Jul 15; 9(3):205-15. PubMed ID: 22228773
    [Abstract] [Full Text] [Related]

  • 30. Effects of rosuvastatin versus atorvastatin, simvastatin, and pravastatin on non-high-density lipoprotein cholesterol, apolipoproteins, and lipid ratios in patients with hypercholesterolemia: additional results from the STELLAR trial.
    Jones PH, Hunninghake DB, Ferdinand KC, Stein EA, Gold A, Caplan RJ, Blasetto JW, Statin Therapies for Elevated Lipid Levels Compared Across Doses to Rosuvastatin Study Group.
    Clin Ther; 2004 Sep 15; 26(9):1388-99. PubMed ID: 15531001
    [Abstract] [Full Text] [Related]

  • 31. Efficacy and safety of combination of extended release niacin and atorvastatin in patients with low levels of high density lipoprotein cholesterol.
    Harikrishnan S, Rajeev E, Tharakan JA, Titus T, Ajit Kumar VK, Sivasankaran S, Krishnamoorthy KM, Nair K.
    Indian Heart J; 2008 Sep 15; 60(3):215-22. PubMed ID: 19240310
    [Abstract] [Full Text] [Related]

  • 32. Efficacy and safety of rosuvastatin 40 mg alone or in combination with ezetimibe in patients at high risk of cardiovascular disease (results from the EXPLORER study).
    Ballantyne CM, Weiss R, Moccetti T, Vogt A, Eber B, Sosef F, Duffield E, EXPLORER Study Investigators.
    Am J Cardiol; 2007 Mar 01; 99(5):673-80. PubMed ID: 17317370
    [Abstract] [Full Text] [Related]

  • 33. Achieving lipoprotein goals in patients at high risk with severe hypercholesterolemia: efficacy and safety of ezetimibe co-administered with atorvastatin.
    Stein E, Stender S, Mata P, Sager P, Ponsonnet D, Melani L, Lipka L, Suresh R, Maccubbin D, Veltri E, Ezetimibe Study Group.
    Am Heart J; 2004 Sep 01; 148(3):447-55. PubMed ID: 15389231
    [Abstract] [Full Text] [Related]

  • 34. Effectiveness of a fenofibrate 145-mg nanoparticle tablet formulation compared with the standard 160-mg tablet in patients with coronary heart disease and dyslipidemia.
    Maciejewski S, Hilleman D.
    Pharmacotherapy; 2008 May 01; 28(5):570-5. PubMed ID: 18447655
    [Abstract] [Full Text] [Related]

  • 35. Efficacy and safety of micronised fenofibrate in a randomised double-blind study comparing four doses from 200 mg to 400 mg daily with placebo in patients with hypercholesterolemia.
    Krempf M, Rohmer V, Farnier M, Issa-Sayegh M, Corda C, Sirugue I, Gerlinger C, Masseyeff-Elbaz MF.
    Diabetes Metab; 2000 May 01; 26(3):184-91. PubMed ID: 10880891
    [Abstract] [Full Text] [Related]

  • 36. Differing effects of low-dose estrogen-progestin therapy and pravastatin in postmenopausal hypercholesterolemic women.
    Davis SR, Goldstat R, Newman A, Berry K, Burger HG, Meredith I, Koch K.
    Climacteric; 2002 Dec 01; 5(4):341-50. PubMed ID: 12626213
    [Abstract] [Full Text] [Related]

  • 37. Effects of fluvastatin extended-release (80 mg) alone and in combination with ezetimibe (10 mg) on low-density lipoprotein cholesterol and inflammatory parameters in patients with primary hypercholesterolemia: a 12-week, multicenter, randomized, open-label, parallel-group study.
    Alvarez-Sala LA, Cachofeiro V, Masana L, Suarez C, Pinilla B, Plana N, Trias F, Moreno MA, Gambus G, Lahera V, Pintó X.
    Clin Ther; 2008 Jan 01; 30(1):84-97. PubMed ID: 18343245
    [Abstract] [Full Text] [Related]

  • 38. Atorvastatin monotherapy vs. combination therapy in the management of patients with combined hyperlipidemia.
    Avisar I, Brook JG, Wolfovitz E.
    Eur J Intern Med; 2008 May 01; 19(3):203-8. PubMed ID: 18395165
    [Abstract] [Full Text] [Related]

  • 39. Lipid-altering efficacy of ezetimibe/simvastatin 10/20 mg compared with rosuvastatin 10 mg in high-risk hypercholesterolaemic patients inadequately controlled with prior statin monotherapy - The IN-CROSS study.
    Farnier M, Averna M, Missault L, Vaverkova H, Viigimaa M, Massaad R, Vandormael K, Johnson-Levonas AO, Brudi P.
    Int J Clin Pract; 2009 Apr 01; 63(4):547-59. PubMed ID: 19222610
    [Abstract] [Full Text] [Related]

  • 40. Attainment of goal/desirable lipid levels in patients with mixed dyslipidemia after 12 weeks of treatment with fenofibric acid and rosuvastatin combination therapy: a pooled analysis of controlled studies.
    Roth EM, Rosenson RS, Jones PH, Davidson MH, Kelly MT, Setze CM, Lele A, Thakker K.
    J Clin Lipidol; 2012 Apr 01; 6(6):534-44. PubMed ID: 23312049
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.